Linked Life Data

20145546

Source:http://linkedlifedata.com/resource/pubmed/id/20145546

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20145546rdf:typepubmed:Citationlld:pubmed
pubmed-article:20145546lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0079460lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0079731lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0439682lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0393022lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20145546lifeskim:mentionsumls-concept:C1327897lld:lifeskim
pubmed-article:20145546pubmed:issue2lld:pubmed
pubmed-article:20145546pubmed:dateCreated2010-2-24lld:pubmed
pubmed-article:20145546pubmed:abstractTextWe evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma. Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously. Courses were given monthly for 6 doses, every 2 months for 6 doses, and then every 3 months until disease progression. Computed tomography scans were obtained every 3 to 6 months and reviewed centrally. The primary endpoint was event-free survival (EFS). Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had stage III to IV disease, and 59% had failed earlier therapy. The premitumprotimut-T objective response rate was 47% (2 CRs, 41 PRs). During the mitumprotimut-T treatment phase, 16 patients converted to CR resulting in an overall objective response rate of 60% (18 CRs, 37 PRs). Median EFS was 15.2, 20.8, and 13.5 months for all, treatment-naive, and relapsed/refractory disease patients, respectively. Anti-Id cellular immune responses were detected in 13 of 18 (72%) patients and humoral immune responses in 17 of 83 (20%) patients. Adverse events were usually mild-to-moderate. The most common adverse event was injection site reactions. Mitumprotimut-T/GM-CSF-induced anti-Id cellular immune responses in most patients. The occurrence of late CRs and favorable EFS suggested a clinical benefit of active immunotherapy and led to a placebo-controlled phase 3 trial.lld:pubmed
pubmed-article:20145546pubmed:languageenglld:pubmed
pubmed-article:20145546pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:citationSubsetIMlld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20145546pubmed:statusMEDLINElld:pubmed
pubmed-article:20145546pubmed:issn1537-4513lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:WiernikPeter...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:RosenfeltFred...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:WinterJane...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:KoçOmer NONlld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:StewartMorgan...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:BenderJohn...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:GhalieRichard...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:RedfernCharle...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:CarterWilliam...lld:pubmed
pubmed-article:20145546pubmed:authorpubmed-author:GoldDan PDPlld:pubmed
pubmed-article:20145546pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20145546pubmed:volume33lld:pubmed
pubmed-article:20145546pubmed:ownerNLMlld:pubmed
pubmed-article:20145546pubmed:authorsCompleteYlld:pubmed
pubmed-article:20145546pubmed:pagination178-84lld:pubmed
pubmed-article:20145546pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:meshHeadingpubmed-meshheading:20145546...lld:pubmed
pubmed-article:20145546pubmed:articleTitleA phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.lld:pubmed
pubmed-article:20145546pubmed:affiliationDepartment of Regional Oncology, Cleveland Clinic, Beachwood, OH 44122, USA. KOCO@ccf.orglld:pubmed
pubmed-article:20145546pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20145546pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20145546pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed